🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

NOW PUBLISHED in Journal of Clinical Oncology: Updated results from the phase I/II BRUIN study, investigating a highly selective, non-covalent (reversible) BTKi in patients w/ covalent BTKi pre-treated #MantleCellLymphoma. #lymsm Read the results here: e.lilly/3Omh2bz

🎥 Nirav Shah of Medical College of Wisconsin discusses the rationale and interim results of a study evaluating split-dose R-CHOP for older patients with advanced-stage #DLBCL👇: ow.ly/TAiM50OZFbt ASCO #LymSM #HemOnc #ImmunoOnc

Excited to be a co-author on my first (hopefully not last) paper in NEJM evaluating outcomes of Pirtobrutinib in CLL after prior covalent BTKi. Data speak for themselves and will be a new option for patients with R/R CLL! nejm.org/doi/full/10.10…

👉👉First time in Nashville for the Binaytara Foundation Hem Summit ! Binay Shah, MD, MHA Fadi Haddad, MD Naveen Pemmaraju, MD Tapan Kadia @sairah__ahmed @BldCancerDoc Soni Smith MD Shaji Kumar Loretta J. Nastoupil, MD Alex Bataller Sanam Loghavi, MD صنم لغوی 🔬🧬 Kamran Mirza MD PhD - کامران مرزا Anand Patel Lori Muffly Nirav Shah

Amazing, and entertaining, session on Aggressive Lymphomas with @sairah__ahmed (MD Anderson Cancer Center), Nirav Shah (Medical College of Wisconsin), and Bhagirath Dholaria, MD & Ola Oluwole of Vanderbilt Health here at #HemeSummit23! Great to see lots of audience participation.

There is no worse thing MDs have to do than a peer to peer for drug approval. Endless time wasted

Pirtobrutinib Monotherapy Demonstrates Early Activity in R/R Follicular Lymphoma Nirav Shah Medical College of Wisconsin ASH #ASH23 #oncology onclive.com/view/pirtobrut…

If you see an eligible DLBCL patient in CR, does #CART outperform AutoHCT? Only available data by CIBMTR Mazyar Shadman, MD MPH Reminds you to keep an open mind, one size does not fit all 🙏🙏 ASH for recognizing our work in Press Release #ASH23

⁦Nirav Shah⁩ presenting our point of care CD19/20 MCL cohort data. N=17. ORR 100%, 88% CR. Only 2 relapses so far. 12% Gr 3 ICANS. No Gr 3-4 CRS. Proud to be part of this work!

In Saturday's #WordOnMedicine podcast, #MCW's Nirav Shah shares how #cancer investigators recently treated the 100th patient in an ongoing #ClinicalTrial using an in-house manufactured, dual-targeted CAR-T therapy for patients with B-cell malignancies: iheart.com/podcast/477-th…

CD19.20 dual CAR in third or later line DLBCL being presented by Nirav Shah #ASH24

CONGRESS | #ASH24 | PRESENTATION Nirav Shah Nirav Shah MCW Hematology & Oncology presents interim results from the phase II DALY II USA study. Zamto-cel demonstrated encouraging efficacy, with an ORR of 72.8%, and there were low incidences of CRS and ICANS in patients with R/R DLBCL.

A rapidly delivered tandem CAR T-cell therapy produced favorable outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma, according to data at #ASH24. Healio spoke with Nirav Shah of Medical College of Wisconsin about the data. #Lymphoma healio.com/news/hematolog…

NX-5948 update in CLL - awesome that they permitted CNS involvement (8%). Tox profile looks good. Enrolled variety of BTK mutants. High ORR and responses may deepen.

Dr. Fenske Tim Fenske presenting this important late breaking abstract Nirav Shah Mehdi Hamadani, MD MCW Cancer Center ASH #ASH2024

Excited to share a publication years in the making, our experience with CAR20.19 T cells in relapsed, refractory Mantle Cell Lymphoma now a. Excellent outcomes from IIT MCW Cancer Center Thanks to great collaborators Tim Fenske Mehdi Hamadani, MD and many more! ascopubs.org/doi/10.1200/JC…

ascopost.com/news/april-202…